Why I Would Buy Big Yellow Group plc, Finsbury Food Group plc And AstraZeneca plc

Royston Wild lays out the investment case for Big Yellow Group plc (LON: BYG), Finsbury Food Group plc (LON: FIF) and AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at three Thursday headline makers that stock pickers should seriously consider.

Big Yellow Group

Storage house Big Yellow Group (LSE: BYG) greeted the market with yet another positive update in Thursday business, in turn pushing shares in the business 1.7% higher on the day. The Bagshot business saw like-for-like revenues leap 10% during April-June, to £20.7m, and its underlying occupancy rate jumped to 76.3% from 71.2% during the corresponding 2014 period.

And Big Yellow said that it expects this occupancy rate to leap another three to four percentage points during the current year, a projection I fully expect the firm to realise as Britons’ hoarding culture — boosted by improving spending power — fuels the need for extra space. This view is shared by the City, and earnings growth of 12% and 13% are pencilled in for the years concluding March 2016 and 2017 correspondingly.

Although Big Yellow sports slightly-elevated P/E ratios of 21.5 times and 19.2 times for these years, I expect these to continue collapsing in line with strong demand. And in my opinion projected dividends of 24.5p per share for 2016 and 27.6p for 2017 more than offsets these multiples, creating chunky yields of 3.8% and 4.2%.

Finsbury Food Group

Like Big Yellow, Finsbury Food Group (LSE: FIF) also cheered investors with a bubbly trading update during today’s session and was consequently dealing 6.3% higher. The stock has gained 54% since the turn of the year, propelling the business to current record highs of 92.5p per share at the current time. But I reckon further hefty gains can be expected.

Finsbury Foods announced that total sales jumped 45.8% during the 12 months concluding June 2015, helped by the recent acquisition of Fletchers. Consequently the specialty baker said it expects to exceed current profit expectations. So current City forecasts of a 10% earnings decline for the year could be set for a significant upgrade given today’s release, while predictions of a 27% increase in the current period could also receive a shot in the arm.

I believe that Finsbury Foods offers brilliant value for money, the caterer boasting an ultra-cheap earnings multiple of 9.8 for 2016 — any reading below 10 times is widely considered too good to pass on. When you factor in a projected dividend of 2.8p per share, too, producing a meaty 3.4% yield, I believe the food manufacturer is a hugely appetising stock pick.

AstraZeneca

Unlike its FTSE compatriots, however, AstraZeneca (LSE: AZN) was recently dealing 0.4% lower in Thursday’s session and this extends the broad downtrend seen during the past few months. However, I believe this current weakness — AstraZeneca has shed 11% since the middle of April — makes the business a bargain at the current time, even though the problem of exclusivity losses looks set to continue.

The number crunchers expect the London firm to arrest the heavy earnings declines of recent years in 2015 with a bottom-line stagnation, although a fresh 3% fall is predicted for 2016. But I am convinced AstraZeneca’s reinvigorated R&D pipeline — combined with surging healthcare demand from emerging regions — makes the business a terrific long-term growth pick. The business received FDA approval for its Iressa lung cancer drug just this week, and AstraZeneca plans to release a further six oncology-related products during the next five years alone.

I consider a prospective P/E multiple of 15.5 times decent value given these hot product prospects, while juicy dividend projections around 285 US cents for 2015 and 2016 cement the investment case in my opinion — these forecasts create a produce market-beating yield of 4.3%.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

Could this cheap FTSE 100 stock be the next Rolls-Royce?

Paul Summers casts his eye over a battered-but-high-quality FTSE 100 stock. Is this the next top-tier company to stage a…

Read more »

ISA Individual Savings Account
Investing Articles

Hesitant over a Stocks and Shares ISA? Here’s a way to deal with scary markets

Volatile stock markets are scaring potential investors away from getting started with their first Stocks and Shares ISA in 2026.

Read more »

This way, That way, The other way - pointing in different directions
Market Movers

Standard Life’s announced a £2bn deal but its share price is largely unchanged. Why?

James Beard considers why the Standard Life share price didn’t take off today (15 April) after the group announced it…

Read more »

Happy parents playing with little kids riding in box
Investing Articles

Up 12% in a month, Hollywood Bowl is a UK dividend stock on a roll

This 5%-yielding dividend stock was one of the top performers in the FTSE 250 index today. What sent it flying…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

Young investors are taking the stock market on a rollercoaster ride. Here’s how retirees can buckle up

Mark Hartley reveals the volatile impact that younger investors are having on the stock market and how UK retirees can…

Read more »

Two female adult friends walking through the city streets at Christmas. They are talking and smiling as they do some Christmas shopping.
Investing Articles

£7,500 invested in Aviva shares 5 years ago is now worth…

A lump sum pumped into Aviva shares half a decade ago has grown a lot. Andrew Mackie looks at the…

Read more »

Young female hand showing five fingers.
Investing Articles

Could £20,000 invested in these 5 dividend shares produce £14,760 of passive income over the next 10 years?

James Beard considers the potential of dividend shares to deliver amazing levels of passive income. Here are five that have…

Read more »

Workers at Whiting refinery, US
Investing Articles

At 570p, is it too late to consider buying BP shares?

Since the end of February, when the conflict in the Middle East started, BP shares have soared nearly 20%. But…

Read more »